{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:11Z","timestamp":1790686211287,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI)-related cytopenias have been poorly described. This study aimed to further characterize ICI-related cytopenias, using the French pharmacovigilance database. All grade \u2265 2 hematological adverse drug reactions involving at least one ICI coded as suspected or interacting drug according to the World Health Organization criteria and reported up to 31 March 2022, were extracted from the French pharmacovigilance database. Patients were included if they experienced ICI-related grade \u2265 2 cytopenia. We included 68 patients (75 ICI-related cytopenias). Sixty-three percent were male, and the median age was 63.0 years. Seven patients (10.3%) had a previous history of autoimmune disease. Immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) were the most frequently reported (50.7% and 25.3%, respectively). The median time to onset of ICI-related cytopenias was 2 months. Nearly half were grade \u2265 4, and three patients died from bleeding complications of refractory ITP and from thromboembolic disease with active AIHA. Out of 61 evaluable responses, complete or partial remission was observed after conventional treatment in 72.1% of ICI-related cytopenias. Among the 10 patients with ICI resumption after grade \u2265 2 ICI-related cytopenia, three relapsed. ICI-related cytopenias are rare but potentially life-threatening. Further studies are needed to identify risk factors of ICI-related cytopenias.<\/jats:p>","DOI":"10.3390\/cancers14205030","type":"journal-article","created":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T21:10:10Z","timestamp":1665954610000},"page":"5030","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database"],"prefix":"10.3390","volume":"14","author":[{"given":"Micka\u00ebl","family":"Martin","sequence":"first","affiliation":[{"name":"Service de M\u00e9decine Interne, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"},{"name":"Facult\u00e9 de M\u00e9decine et de Pharmacie, Universit\u00e9 de Poitiers, 86000 Poitiers, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1313, Universit\u00e9 de Poitiers, 86000 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoan-My","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Beuvon","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"},{"name":"Facult\u00e9 de M\u00e9decine et de Pharmacie, Universit\u00e9 de Poitiers, 86000 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johana","family":"Bene","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance du Nord-Pas de Calais, Centre Hospitalier Universitaire de Lille, 59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2717-9437","authenticated-orcid":false,"given":"Pascale","family":"Palassin","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, 34295 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Atzenhoffer","sequence":"additional","affiliation":[{"name":"Service Hospitalo, Universitaire de Pharmaco-Toxicologie, Hospices Civils de Lyon, 69424 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Rouby","sequence":"additional","affiliation":[{"name":"CRPV Marseille Provence Corse, Service Hospitalo, Universitaire de Pharmacologie Clinique et Pharmacovigilance, Assistance Publique H\u00f4pitaux de Marseille, 13385 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Sassier","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pharmacologie, Centre Hospitalier Universitaire de Caen, 14033 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"P\u00e9rault-Pochat","sequence":"additional","affiliation":[{"name":"Pharmacologie Clinique et Vigilances, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"},{"name":"Laboratoire de Neurosciences Exp\u00e9rimentales et Cliniques, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1084, Universit\u00e9 de Poitiers, 86000 Poitiers, France"},{"name":"Centre d\u2019Investigation Clinique-1402, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Roblot","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"},{"name":"Facult\u00e9 de M\u00e9decine et de Pharmacie, Universit\u00e9 de Poitiers, 86000 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Allouchery","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine et de Pharmacie, Universit\u00e9 de Poitiers, 86000 Poitiers, France"},{"name":"Pharmacologie Clinique et Vigilances, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5639-0138","authenticated-orcid":false,"given":"Mathieu","family":"Puyade","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"},{"name":"Centre d\u2019Investigation Clinique-1402, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","article-title":"PD-Loma: A Cancer Entity with a Shared Sensitivity to the PD-1\/PD-L1 Pathway Blockade","volume":"120","author":"Hirsch","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-Related Adverse Events of Checkpoint Inhibitors","volume":"6","author":"Brahmer","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint Blockade in Cancer Immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-Related Hematological Adverse Events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological Immune Related Adverse Events after Treatment with Immune Checkpoint Inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic Complications of Immune Checkpoint Inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune Hemolytic Anemia Associated with the Use of Immune Checkpoint Inhibitors for Cancer: 68 Cases from the Food and Drug Administration Database and Review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_9","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"Evreux","year":"1985","journal-title":"Therapie"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The Medical Dictionary for Regulatory Activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A Randomized and Double-Blind Controlled Trial Evaluating the Safety and Efficacy of Rituximab for Warm Auto-Immune Hemolytic Anemia in Adults (the RAIHA Study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of Terminology, Definitions and Outcome Criteria in Immune Thrombocytopenic Purpura of Adults and Children: Report from an International Working Group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.autrev.2009.03.006","article-title":"Autoimmune Neutropenia in Adults","volume":"9","author":"Akhtari","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/asheducation-2016.1.51","article-title":"Pure Red Cell Aplasia","volume":"2016","author":"Means","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(88)90388-1","article-title":"Criteria for Severe Aplastic Anaemia","volume":"1","author":"Camitta","year":"1988","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000511759","article-title":"Hematological Manifestations among Patients with Rheumatic Diseases","volume":"144","author":"Klein","year":"2021","journal-title":"Acta Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/17474086.2018.1489720","article-title":"Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: A Concise Review and Treatment Recommendations","volume":"11","author":"Kater","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00018-009-0209-x","article-title":"Platelets and Viruses: An Ambivalent Relationship","volume":"67","author":"Flaujac","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1017\/S0950268818001206","article-title":"Thrombocytopenia in Bacteraemia and Association with Bacterial Species","volume":"146","author":"Johansson","year":"2018","journal-title":"Epidemiol. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune Hemolytic Anemia: Current Knowledge and Perspectives","volume":"17","author":"Michalak","year":"2020","journal-title":"Immun. Ageing"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.hoc.2018.03.001","article-title":"The Pathophysiology of Acquired Aplastic Anemia: Current Concepts Revisited","volume":"32","author":"Schoettler","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e001622","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of Immune Checkpoint Inhibitor Rechallenge after Discontinuation for Grade \u22652 Immune-Related Adverse Events in Patients with Cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological Immune-Related Adverse Events Induced by Anti-PD-1 or Anti-PD-L1 Immunotherapy: A Descriptive Observational Study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological Immune-Related Adverse Events with Immune Checkpoint Inhibitors, How to Manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/blood-2019-132203","article-title":"Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series","volume":"134","author":"Gnanapandithan","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune Checkpoint Inhibitor-Related Thrombocytopenia: Incidence, Risk Factors and Effect on Survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of Toxicities of Immune Checkpoint Inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge Patients with Immune Checkpoint Inhibitors Following Severe Immune-Related Adverse Events: Review of the Literature and Suggested Prophylactic Strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.04.004","article-title":"Immune-Related Bone Marrow Failure Following Anti-PD1 Therapy","volume":"80","author":"Michot","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2008.01095.x","article-title":"Increased T Cell Immunoglobulin Mucin-3 and Its Ligand in Acquired Aplastic Anemia","volume":"81","author":"Zhang","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2017.01.016","article-title":"High Programmed Death 1 Expression on T Cells in Aplastic Anemia","volume":"183","author":"Zhao","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic Complications of Immune Checkpoint Inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coi.2021.02.002","article-title":"Adverse Events Induced by Immune Checkpoint Inhibitors","volume":"69","author":"Perdigoto","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-Reporting of Adverse Drug Reactions: A Systematic Review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of Under-Reporting of Adverse Drug Reactions: A Systematic Review","volume":"32","author":"Herdeiro","year":"2009","journal-title":"Drug Saf."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5030\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:53:52Z","timestamp":1760144032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":36,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14205030"],"URL":"https:\/\/doi.org\/10.3390\/cancers14205030","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}